MX2017016509A - Particulas de dimetilfumarato y composiciones farmaceuticas de estas. - Google Patents
Particulas de dimetilfumarato y composiciones farmaceuticas de estas.Info
- Publication number
- MX2017016509A MX2017016509A MX2017016509A MX2017016509A MX2017016509A MX 2017016509 A MX2017016509 A MX 2017016509A MX 2017016509 A MX2017016509 A MX 2017016509A MX 2017016509 A MX2017016509 A MX 2017016509A MX 2017016509 A MX2017016509 A MX 2017016509A
- Authority
- MX
- Mexico
- Prior art keywords
- particles
- dimethyl fumarate
- dmf
- pharmaceutical compositions
- fumarate particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona partículas de dimetilfumarato (DMF) y métodos de preparación de las partículas de DMF, también se proporcionan partículas recubiertas de DMF que comprenden partículas de DMF recubiertas con un recubrimiento entérico, la invención proporciona también diversas formas de dosificación y métodos para tratar una enfermedad o trastorno (por ejemplo, la esclerosis múltiple).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562181061P | 2015-06-17 | 2015-06-17 | |
PCT/US2016/037486 WO2016205270A1 (en) | 2015-06-17 | 2016-06-15 | Dimethyl fumarate particles and pharmaceutical compositions thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017016509A true MX2017016509A (es) | 2018-08-16 |
Family
ID=56292916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016509A MX2017016509A (es) | 2015-06-17 | 2016-06-15 | Particulas de dimetilfumarato y composiciones farmaceuticas de estas. |
Country Status (13)
Country | Link |
---|---|
US (2) | US11291642B2 (es) |
EP (1) | EP3310341A1 (es) |
JP (2) | JP2018517735A (es) |
KR (1) | KR20180018711A (es) |
CN (1) | CN107920997A (es) |
AU (2) | AU2016279997B2 (es) |
CA (1) | CA2989581A1 (es) |
EA (1) | EA201890068A1 (es) |
HK (1) | HK1254054A1 (es) |
IL (1) | IL256296A (es) |
MA (1) | MA42196A (es) |
MX (1) | MX2017016509A (es) |
WO (1) | WO2016205270A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018008835A8 (pt) * | 2015-10-28 | 2019-02-26 | Sun Pharmaceutical Ind Ltd | composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla |
CA3013472A1 (en) * | 2016-02-11 | 2017-08-17 | Biogen Ma Inc. | Pharmaceutical bead formulations comprising dimethyl fumarate |
IL273553B1 (en) * | 2017-10-02 | 2024-05-01 | Novartis Ag | A method for preparing a pharmacy product |
US11318682B2 (en) | 2018-04-06 | 2022-05-03 | Hewlett-Packard Development Company, L.P. | Three-dimensional (3D) object printing based on build material permeability |
JP2022504333A (ja) * | 2018-10-05 | 2022-01-13 | アイエスピー インヴェストメンツ エルエルシー | 水溶性セルロースエーテルを含有する平滑な高固形分フィルムコーティング組成物、その調製方法およびその使用方法 |
TR201818293A2 (tr) * | 2018-11-30 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül |
JP2022525926A (ja) * | 2019-03-20 | 2022-05-20 | リンドラ セラピューティクス, インコーポレイティド | 胃内滞留剤形用のカプセル及びカプセルコーティング |
US11590071B2 (en) * | 2021-07-06 | 2023-02-28 | King Abdulaziz University | Injectable drug delivery implant composition and method of use thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
DE14172398T1 (de) * | 2004-10-08 | 2015-01-08 | Forward Pharma A/S | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester |
TR201902010T4 (tr) | 2006-01-18 | 2019-03-21 | Intec Pharma Ltd | Bir ajanın oral alımına yönelik taşıyıcı cihaz. |
EP2276473B1 (en) * | 2008-04-18 | 2016-09-14 | Intec Pharma Ltd. | Gastroretentive drug delivery for carbidopa/levodopa |
WO2010079221A1 (en) * | 2009-01-09 | 2010-07-15 | Forward Pharma A/S | Pharmaceutical composition comprising one or more fumaric acid esters |
PT2564839T (pt) * | 2009-01-09 | 2016-07-14 | Forward Pharma As | Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão |
HUE036085T2 (hu) * | 2011-06-08 | 2018-06-28 | Biogen Ma Inc | Nagy tisztaságú és kristályos dimetil-fumarát elõállítására szolgáló eljárás |
RU2014125430A (ru) * | 2011-11-24 | 2015-12-27 | Синтон Бв | Контролируемое высвобождение частиц, содержащих диметилфумарат |
CN114146079A (zh) * | 2012-02-07 | 2022-03-08 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
WO2015042294A1 (en) | 2013-09-18 | 2015-03-26 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
WO2015044853A2 (en) * | 2013-09-25 | 2015-04-02 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for preparation of dimethyl fumarate |
US10172794B2 (en) | 2013-12-13 | 2019-01-08 | Biogen Ma Inc. | Controlled release dosage form for once daily administration of dimethyl fumarate |
DK3110408T3 (en) * | 2014-02-28 | 2019-04-29 | Banner Life Sciences Llc | ENTERY SOFT CAPS OF CONTROLLED RELEASE FUMAR TESTERS |
-
2016
- 2016-06-15 EP EP16733793.0A patent/EP3310341A1/en not_active Withdrawn
- 2016-06-15 KR KR1020187001091A patent/KR20180018711A/ko not_active Application Discontinuation
- 2016-06-15 MX MX2017016509A patent/MX2017016509A/es unknown
- 2016-06-15 EA EA201890068A patent/EA201890068A1/ru unknown
- 2016-06-15 JP JP2017565133A patent/JP2018517735A/ja active Pending
- 2016-06-15 US US15/737,011 patent/US11291642B2/en active Active
- 2016-06-15 AU AU2016279997A patent/AU2016279997B2/en not_active Ceased
- 2016-06-15 CN CN201680047251.2A patent/CN107920997A/zh active Pending
- 2016-06-15 MA MA042196A patent/MA42196A/fr unknown
- 2016-06-15 CA CA2989581A patent/CA2989581A1/en active Pending
- 2016-06-15 WO PCT/US2016/037486 patent/WO2016205270A1/en active Application Filing
-
2017
- 2017-12-13 IL IL256296A patent/IL256296A/en unknown
-
2018
- 2018-10-12 HK HK18113117.1A patent/HK1254054A1/zh unknown
-
2021
- 2021-11-12 JP JP2021184469A patent/JP2022042512A/ja active Pending
-
2022
- 2022-01-12 AU AU2022200155A patent/AU2022200155A1/en not_active Abandoned
- 2022-02-22 US US17/677,204 patent/US20220362195A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20190070143A1 (en) | 2019-03-07 |
KR20180018711A (ko) | 2018-02-21 |
JP2022042512A (ja) | 2022-03-14 |
HK1254054A1 (zh) | 2019-07-12 |
MA42196A (fr) | 2018-04-25 |
AU2022200155A1 (en) | 2022-02-10 |
AU2016279997A1 (en) | 2018-01-18 |
EA201890068A1 (ru) | 2018-09-28 |
US20220362195A1 (en) | 2022-11-17 |
JP2018517735A (ja) | 2018-07-05 |
AU2016279997B2 (en) | 2021-10-21 |
CA2989581A1 (en) | 2016-12-22 |
WO2016205270A8 (en) | 2017-01-19 |
US11291642B2 (en) | 2022-04-05 |
CN107920997A (zh) | 2018-04-17 |
WO2016205270A1 (en) | 2016-12-22 |
IL256296A (en) | 2018-02-28 |
EP3310341A1 (en) | 2018-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017016509A (es) | Particulas de dimetilfumarato y composiciones farmaceuticas de estas. | |
ZA202103669B (en) | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use | |
PH12018501281A1 (en) | Human immunodeficiency virus neutralizing antibodies | |
ZA201903932B (en) | Imidazopyrazine inhibitors of bruton's tyrosine kinase | |
SG11201707452YA (en) | Scratch resistant, easy-to-clean coatings, methods of producing the same and the use thereof | |
IL275482A (en) | Asketamine for the treatment of depression | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
EP4021559C0 (en) | DELIVERY OF TUMOR TREATMENT FIELDS (TTFIELDS) TO THE NECK | |
MA39803A (fr) | Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation | |
MX2019005322A (es) | Composiciones de recubrimiento y metodos de uso de las mismas. | |
MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
IL283948A (en) | Methods for treating depression | |
MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
SG11201705450SA (en) | Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases | |
SG11202111701XA (en) | Coated drug compositions and methods of preparing the same | |
EP3429598A4 (en) | COMPOSITIONS AND METHODS FOR TREATING BETA-CATENIN-ASSOCIATED DISEASE OR DISORDERS | |
HK1257588A1 (zh) | 預防和治療肺纖維化的藥物及其用途 | |
EP3449942A4 (en) | METHOD FOR TREATING MULTIPLE SCLEROSIS | |
IL286000A (en) | Asketamine for the treatment of depression | |
WO2016123329A3 (en) | Gene expression markers and treatment of multiple sclerosis | |
IL261984B (en) | Sultiame for the treatment of sleep apnea | |
IL269681A (en) | New methods for treating multiple sclerosis | |
MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
IL271791A (en) | Salt of (ss)-adenosyl methionine with inositol hexaphosphate, and process for the preparation thereof | |
ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease |